Additional analysis of data obtained from the EudraVigilance database, with review of individual cases (the conclusions and recommendations are based on the results of a search of the EudraVigilance database with a cut-off date of 22 March 2021) and of the literature, indicating a signal of embolic and thromboembolic events, cerebral venous sinus thrombosis, splanchnic vein thrombosis, and arterial thrombosis with or without thrombocytopenia. Most cases were recorded in women under 60 years of age, with the time to onset of the event being up to two weeks after vaccination.
According to experts, the most plausible hypothesis for cases of thrombosis in combination with thrombocytopenia is a condition similar to atypical heparin-induced thrombocytopenia (aHIT), given the similarity of both the serological profile and the clinical picture in patients. The aHIT-like syndrome is believed to be associated with anti-PF4 autoantibodies that show high binding affinity. It has been hypothesized that the antibody itself may alter the structure of PF4, similar to aHIT syndrome. High titers of antibodies against PF4 were found in all patients, which supports this hypothesis.
PRAC considers that a causal relationship between vaccination with Vaxzevria/COVID-19 AstraZeneca and the described adverse events is at least possible.
A number of additional studies will be conducted to determine the exact pathophysiological mechanism of these thrombotic events and to determine the exact magnitude of the risk.
PRAC recommends that the registration certificate holder of Vaxzevria/COVID-19 AstraZeneca submit an application for changes to the instructions for medical use, as specified below (new text underlined in bold, deleted text struck through).
Section “Special warnings and precautions for use”
Thrombocytopenia and blood coagulation disorders
The combination of thrombosis and thrombocytopenia, in some cases accompanied by bleeding, has been observed very rarely after vaccination with Vaxzevria/COVID-19 AstraZeneca. This includes severe cases presenting as venous thrombosis in unusual sites, such as cerebral venous sinus thrombosis, splanchnic vein thrombosis, mesenteric vein thrombosis, as well as arterial thrombosis accompanied by thrombocytopenia. Some cases had a fatal outcome. Most of these cases occurred within the first seven to fourteen days after vaccination and were observed mainly in women under 55 years of age and 60 years of age, however, this may reflect the increased use of the vaccine in this population. Some cases had a fatal outcome.
Healthcare professionals should pay attention to the symptoms and signs of thromboembolism and thrombocytopenia. Vaccinated individuals should seek medical attention immediately if, after vaccination, they develop symptoms such as shortness of breath, chest pain, leg swelling, or persistent abdominal pain. In addition, in the presence of neurological symptoms, including severe or persistent headaches, blurred vision, confusion, or seizures after vaccination, or petechiae beyond the site of vaccination that appear after several days, medical attention must be sought immediately.
“Adverse reactions” section
The following adverse reactions should be added under the system organ class “Blood and lymphatic system disorders” with the frequency “common”: thrombocytopenia
The following adverse reaction should be added under the system organ class “Vascular disorders” with the frequency “very rare”: Thrombosis in combination with thrombocytopenia *
* Severe and very rare cases of thrombosis in combination with thrombocytopenia have been reported. These included venous thrombosis, such as cerebral venous sinus thrombosis, splanchnic vein thrombosis, as well as arterial thrombosis (see Section “Special warnings and precautions for use”).
Linkhttps://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-6-9-april-2021-prac-meeting_en.pdf